Overview

Randomized Pre-surgical Window-of-Opportunity Trial of TTI-101 in Patients With Stage II-IV Resectable HPV-negative Squamous Cell Carcinoma of the Head and Neck

Status:
Not yet recruiting
Trial end date:
2025-02-01
Target enrollment:
Participant gender:
Summary
To learn if TTI-101 can reduce the growth of HPV-negative squamous cell carcinomas of the head and neck when given before standard of care surgery.
Phase:
Early Phase 1
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborators:
National Institutes of Health (NIH)
Tvardi Therapeutics, Inc